Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized, double-blind, placebo-controlled study of oral PTG-100 induction in moderate to severe active ulcerative colitis
2016-003452-75Phase 2Terminated
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Nov 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of PTG-100 in autoimmune colitis, sponsored by Protagonist Therapeutics, Inc.. Started Nov 2016; status: terminated.
02
Drugs
PTG-100
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2016-003452-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003452-75.